Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

NCT01864096 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01864096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01864096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2013
Completion date
August 31, 2024
Enrollment
408 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer